MiMedx Group (NASDAQ:MDXG - Get Free Report) is anticipated to issue its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $94.7350 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Monday, November 13th. The company reported ($0.03) EPS for the quarter. MiMedx Group had a net margin of 8.84% and a return on equity of 23.03%. The firm had revenue of $67.69 million for the quarter. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
MiMedx Group Price Performance
Shares of MiMedx Group stock opened at $6.74 on Wednesday. The business has a 50 day simple moving average of $7.02 and a two-hundred day simple moving average of $6.78. MiMedx Group has a 12 month low of $5.59 and a 12 month high of $10.14. The stock has a market capitalization of $997.25 million, a P/E ratio of 32.10 and a beta of 1.73. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.39 and a quick ratio of 3.90.
Analysts Set New Price Targets
MDXG has been the subject of a number of analyst reports. Weiss Ratings restated a "hold (c)" rating on shares of MiMedx Group in a research report on Wednesday, October 8th. Wall Street Zen upgraded MiMedx Group from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Finally, Cantor Fitzgerald upped their price target on MiMedx Group from $11.00 to $12.00 and gave the company an "overweight" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, MiMedx Group presently has a consensus rating of "Moderate Buy" and a consensus target price of $12.00.
Get Our Latest Research Report on MDXG
Institutional Trading of MiMedx Group
Several hedge funds have recently modified their holdings of the stock. Millennium Management LLC increased its holdings in MiMedx Group by 93.9% in the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company's stock valued at $9,355,000 after buying an additional 596,016 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in MiMedx Group by 25.2% in the second quarter. Qube Research & Technologies Ltd now owns 1,185,747 shares of the company's stock valued at $7,245,000 after buying an additional 238,919 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in MiMedx Group by 22.7% in the first quarter. Goldman Sachs Group Inc. now owns 1,121,814 shares of the company's stock valued at $8,526,000 after buying an additional 207,397 shares during the last quarter. Royal Bank of Canada increased its holdings in MiMedx Group by 1.4% in the first quarter. Royal Bank of Canada now owns 982,532 shares of the company's stock valued at $7,466,000 after buying an additional 13,629 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in MiMedx Group by 12.6% in the second quarter. JPMorgan Chase & Co. now owns 627,405 shares of the company's stock valued at $3,833,000 after buying an additional 70,147 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors and hedge funds.
MiMedx Group Company Profile
(
Get Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
